Genetic testing for personalized medication in stroke patients
Official title: Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
Run by University of Alabama at Birmingham · NCT06943586 · Data updated 2026-11-12
This study is testing if using genetic testing can help doctors choose the best medication for stroke patients to improve their treatment and recovery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 89 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Status | Recruiting |
| Started | April 9, 2025 |
| Main results expected | April 1, 2028 |
| Study ends | April 1, 2029 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT06943586 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-89 who are admitted to the hospital with symptoms of minor ischemic stroke or high-risk TIA and can receive dual antiplatelet therapy.
✕Probably not a fit
Patients with conditions such as atrial fibrillation, valvular heart disease, or those who have received certain treatments like intravenous thrombolysis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot clinical trial investigates the feasibility of using CYP2C19 genetic testing to guide dual antiplatelet therapy (DAPT) for patients experiencing minor ischemic strokes or high-risk transient ischemic attacks (TIAs). The study aims to determine if personalized medicine can enhance medication decisions made by physicians during hospital stays. By assessing patients' genetic profiles, the trial seeks to optimize treatment strategies and improve outcomes for this vulnerable population.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and tailored medication regimens for stroke and TIA patients, potentially improving recovery and reducing complications.
How similar studies have gone: While this approach is innovative, similar studies exploring pharmacogenomics in other conditions have shown promise, suggesting potential for success in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18-89 years of age * admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA * eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well) Exclusion Criteria: * diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%) * prescribed anticoagulation prior to stroke * treated with intravenous thrombolysis * treated with mechanical thrombectomy * missing NIH Stroke Scale score
Where it's running
-
University of Alabama at Birmingham
Birmingham, Alabama, United States Recruiting
Study contacts
- Principal investigator: Ekaterina Bakradze, MD — University of Alabama at Birmingham
- Study coordinator: Ekaterina Bakradze, MD
- Email: ebakradze@uabmc.edu
- Phone: 205-975-8569
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing Cocoon vs Amplatzer PFO Occluders in Adults After Stroke or TIA
This trial tests whether the Cocoon PFO Occluder works as well as the Amplatzer PFO Occluder in adults who had a cryptogenic stroke or TIA and have a PFO requiring closure.
-
Cardiovascular risk in people with Crohn's disease and ulcerative colitis
This study tests whether people with inflammatory bowel disease have different heart-attack or stroke risk over two years compared with matched controls.
-
Deep phenotyping to explore recovery in young adults after stroke
This project will test whether a detailed health and sample-collection approach (deep phenotyping) is practical and acceptable for people aged 18–55 who have had a stroke.
-
Stem cell therapy for chronic stroke recovery
This study is testing whether using a patient's own stem cells can help people with long-term stroke recovery feel better and improve their daily functioning.
-
Registry of stroke cases in Brest
This study is collecting information on stroke cases in Brest to see how common strokes are, understand their impact on patients, and find better ways to treat them.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.